Disclosures under Reg.13(4) of SEBI (Prohibition of Insider Trading) Regulations, 1992
Ganesh N Nayak has submitted the disclosures under Reg.13(4) of SEBI (Prohibition of Insider Trading) Regulations, 199202-12-2014
02-12-2014
Results Press Release
Cadila Healthcare Ltd has submitted to BSE a copy of the Results Press Release for the period ended September 30, 2014.11-11-2014
Announces Q2 results & Limited Review Report for the Quarter ended September 30, 2014
Cadila Healthcare Ltd has announced the following results for the quarter ended September 30, 2014:The Unaudited Standalone results for the Quarter ended September 30, 2014The Company has posted a net profit of Rs. 3656.10 million for the quarter ended September 30, 2014 as compared to Rs. 1517.60 million for the quarter ended September 30, 2013. Total Income has increased from Rs. 9936.90 million for the quarter ended September 30,...06-11-2014
Shareholding Pattern For September 30, 2014
Cadila Healthcare Ltd has informed BSE about the Shareholding Pattern as on September 30, 2014.16-10-2014
Q2 results on Nov 06, 2014
Cadila Healthcare Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on November 06, 2014, inter alia, to consider and approve the unaudited financial results for the quarter/half-year ended on September 30, 2014 (Q2).Further, as per code of conduct for prevention of Insider Trading adopted by the Company under SEBI (Prohibition of Insider Trading) Regulations, 1992, the Trading Window will remain close...13-10-2014
Investors Presentation
Cadila Healthcare Ltd has submitted to BSE a copy of Presentation, which the Company's Chairman and Managing Director proposed to present to the Investors in U.S.A. during his visit at U.S.A. in this month to bring to the notice of members of exchange and investors at large.04-10-2014
Zydus receives tentative approval for Glipizide ER tablets
Cadila Healthcare Ltd has informed BSE regarding a Press Release dated September 16, 2014, titled "Zydus receives tentative approval for Glipizide ER tablets"16-09-2014
Zydus and Gilead Enter into a Generic Licensing Agreement to manufacture breakthrough treatment for Hepatitis C
Cadila Healthcare Ltd has informed BSE regarding a Press Release dated September 15, 2014 titled "Zydus and Gilead Enter into a Generic Licensing Agreement to manufacture breakthrough treatment for Hepatitis C".15-09-2014
Zydus receives final approval for Telmisartan Tablets
Cadila Healthcare Ltd has informed BSE regarding a Press Release dated August 29, 2014 titled "Zydus receives final approval for Telmisartan Tablets".30-08-2014
Zydus receives final approval for Acyclovir Tablets
Cadila Healthcare Ltd has informed BSE regarding a Press Release dated August 20, 2014 titled "Zydus receives final approval for Acyclovir Tablets".20-08-2014